Biogen

OverviewSuggest Edit

Biogen is a biotechnology company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases. It is primarily focused on developing medicines to treat multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The company also manufactures and commercializes biosimilars of advanced biologics.
TypePublic
Founded1978
HQCambridge, MA, US
Websitebiogen.com
Employee Ratings4
Overall CultureA

Latest Updates

Employees (est.) (Dec 2021)9,610(+6%)
Job Openings248
Revenue (FY, 2021)$11 B(-18%)
Share Price (May 2022)$204.2
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Biogen

Michel Vounatsos

Michel Vounatsos

Chief Executive Officer and Director
Stelios Papadopoulos

Stelios Papadopoulos

Chairman of the Board
Susan Alexander

Susan Alexander

Chief Legal Officer and Secretary
Michael McDonnell

Michael McDonnell

Chief Financial Officer
Ginger Gregory

Ginger Gregory

Chief Human Resources Officer
Maha Radhakrishnan

Maha Radhakrishnan

Group SVP, Chief Medical Officer
Show more

Biogen Office Locations

Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 41 other locations
Cambridge, MA, US (HQ)
225 Binney St
Morrisville, NC, US
5000 Davis Dr
Waltham, MA, US
203 Crescent St #303
Washington, DC, US
701 Pennsylvania Avenue NW #715
Weston, MA, US
133 Boston Post Rd
Vicente López, AR
7th Floor, Av. del Libertador 350
Show all (46)

Biogen Financials and Metrics

Biogen Revenue

Embed Graph
View revenue for all periods
Biogen's revenue was reported to be $10.98 b in FY, 2021 which is a 18.3% decrease from the previous period.
USD

Revenue (FY, 2021)

11.0b

Revenue growth (FY, 2020 - FY, 2021), %

(18.3%)

Gross profit (FY, 2021)

8.9b

Gross profit margin (FY, 2021), %

80.8%

Net income (FY, 2021)

1.7b

EBIT (FY, 2021)

2.8b

Market capitalization (26-May-2022)

29.3b

Closing stock price (26-May-2022)

204.2

Cash (31-Dec-2021)

2.3b

EV

34.7b
Biogen's current market capitalization is $29.3 b.
Annual
USDFY, 2019FY, 2020FY, 2021

Revenue

14.4b13.4b11.0b

Revenue growth, %

7%(6%)(18%)

Cost of goods sold

2.0b1.8b2.1b

Gross profit

12.4b11.6b8.9b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

3.5b3.6b3.6b3.5b3.7b3.4b2.7b2.8b2.8b

Cost of goods sold

602.0m476.3m430.0m454.3m411.1m449.1m478.1m459.7m511.8m

Gross profit

2.9b3.1b3.2b3.1b3.3b2.9b2.2b2.3b2.3b

Gross profit Margin, %

83%87%88%87%89%87%82%83%82%
Annual
USDFY, 2019FY, 2020FY, 2021

Cash

2.9b1.3b2.3b

Accounts Receivable

1.9b1.9b1.5b

Inventories

804.2m1.1b1.4b

Current Assets

8.4b6.9b7.9b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

2.2b1.7b2.3b2.6b2.4b2.2b1.2b1.7b1.5b

Accounts Receivable

2.1b2.0b1.9b2.1b2.1b2.0b1.9b1.7b1.7b

Inventories

770.2m776.7m751.8m858.8m952.7m1.0b1.2b1.3b1.3b

Current Assets

8.9b7.9b8.4b8.0b8.5b7.8b6.7b7.2b7.2b
Annual
USDFY, 2019FY, 2020FY, 2021

Net Income

5.9b4.1b1.7b

Depreciation and Amortization

680.6m457.2m487.7m

Inventories

(19.2m)(316.3m)(462.4m)

Cash From Operating Activities

7.1b4.2b3.6b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

1.4b2.9b4.4b1.4b3.0b3.7b404.6m1.4b1.7b

Depreciation and Amortization

121.1m238.1m567.6m119.9m232.8m366.8m146.9m219.8m353.0m

Inventories

(129.0m)(108.7m)(47.3m)62.2m(188.2m)(270.6m)(112.5m)(193.8m)(322.6m)

Cash From Operating Activities

1.5b3.4b5.1b1.5b3.4b4.6b769.0m2.0b2.8b
USDQ1, 2019

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

1.9 x
Show all financial metrics

Biogen Operating Metrics

FY, 2016FY, 2017FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020Q3, 2020

Phase I Trials Products

447689991113

Phase I/II Trials Products

1

Phase II Trials Products

1012131312121110109

Phase III Trials Products

2343556666

Biogen Acquisitions / Subsidiaries

Company NameDateDeal Size
Nightstar Therapeutics plcJune 01, 2019$744.4 m
Convergence PharmaceuticalsFebruary 12, 2015$474.6 m
TYSABRIApril 02, 2013$3.26 b
Stromedix, Inc.March 08, 2012$207.4 m
Panima Pharmaceuticals AGDecember 01, 2010$113.7 m
Syntonix Pharmaceuticals, Inc.January 04, 2007$44.4 m
FumapharmJune 15, 2006$254.5 m
Conforma TherapeuticsMay 03, 2006$150.5 m
IDEC Pharmaceuticals CorporationNovember 12, 2003$6.8 b
BIIB Colombia S.A.S.
Show more

Biogen Revenue Breakdown

Embed Graph

Biogen revenue breakdown by business segment: 80.6% from Product Revenues, 15.1% from Anti-CD20 Therapeutic Programs and 4.3% from Other

Human Capital Metrics

Embed Graph

Biogen Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

Biogen Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Biogen Online and Social Media Presence

Embed Graph

Biogen Company Culture

  • Overall Culture

    A

    76/100

  • CEO Rating

    B

    71/100

  • Compensation

    A+

    91/100

  • Diversity

    B

    73/100

Learn more on Comparably

Biogen News and Updates

BIIB 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action

SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Biogen Inc. (NASDAQ: BIIB) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.

Biogen submits Phase 4 study protocol for Alzheimer's disease drug

Biogen Inc. said Wednesday it submitted the study protocol to the Food and Drug Administration for a confirmatory clinical trial for Aduhelm, its Alzheimer's disease drug. The regulator approved Aduhelm a year ago under the condition that a confirmatory trial would be conducted. Biogen said it expe…

BIIB 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action

SAN FRANCISCO, March 29, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Biogen Inc. (NASDAQ: BIIB) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.

Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis

CAMBRIDGE, Mass. and CARLSBAD, Calif. , March 28, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx), an investigational antisense oligonucleotide (ASO) for people with C9…

Voyager names former Biogen executive Alfred Sandrock as CEO

Shares of Voyager Therapeutics Inc. gained 2.9% in premarket trading on Tuesday after the gene therapy company said it hired former Biogen Inc. executive Dr. Alfred Sandrock Jr. as its CEO. Sandrock replaces interim CEO Michael Higgins, who will remain board chair. Sandrock is the former chief med…

Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference

CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data and updates from its SPINRAZA® (nusinersen) and spinal muscular atrophy (SMA) research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RES…
Show more

Biogen Blogs

Biogen’s Statement on the Final National Coverage Determination for Amyloid-Beta Targeting Therapies for the Treatment of Alzheimer’s Disease

This unprecedented CMS decision effectively denies all Medicare beneficiaries access to ADUHELM® (aducanumab-avwa), the first and only FDA-approved therapy in a new class of Alzheimer’s drugs. It may also limit coverage for any future approved treatment in the class.

Biogen to Report First Quarter 2022 Financial Results May 3, 2022

Biogen to Report First Quarter 2022 Financial Results May 3, 2022 Ray.Beron@west.com Tue, 04/05/2022 - 13:17 Biogen to Report First Quarter 2022 Financial Results May 3, 2022 April 5, 2022 This release is a backfill from a News Wire Inve…

Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA

Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA Content Import Wed, 03/30/2022 - 07:31 Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA March 30, 2022 This release is a backf…

Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship to Clinical Outcomes and Dosing Regimens - Presented at AD/PD™ 2022 Annual Meeting

Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship to Clinical Outcomes and Dosing Regimens - Presented at AD/PD™ 2022 Annual Meeting ronfrancis.gon… Mon, 03/21/2022 - 17:43 Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relation…

The National Minority Quality Forum and Biogen Highlight Equitable Access to Research and Care in Real World Evidence White Paper

The National Minority Quality Forum and Biogen Highlight Equitable Access to Research and Care in Real World Evidence White Paper Ray.Beron@west.com Fri, 03/18/2022 - 11:42 The National Minority Quality Forum and Biogen Highlight Equitable Access to Research and Care in Real World Evidence…

Biogen to Participate in the Stifel 2022 CNS Days

Biogen to Participate in the Stifel 2022 CNS Days Ray.Beron@west.com Thu, 03/17/2022 - 13:13 Biogen to Participate in the Stifel 2022 CNS Days March 17, 2022 This release is a backfill from a News Wire Investor Relations …
Show more

Biogen Frequently Asked Questions

  • When was Biogen founded?

    Biogen was founded in 1978.

  • Who are Biogen key executives?

    Biogen's key executives are Michel Vounatsos, Stelios Papadopoulos and Susan Alexander.

  • How many employees does Biogen have?

    Biogen has 9,610 employees.

  • What is Biogen revenue?

    Latest Biogen annual revenue is $11 b.

  • What is Biogen revenue per employee?

    Latest Biogen revenue per employee is $1.1 m.

  • Who are Biogen competitors?

    Competitors of Biogen include Omega Therapeutics, Cassava Sciences and Labcorp Drug Development.

  • Where is Biogen headquarters?

    Biogen headquarters is located at 225 Binney St, Cambridge.

  • Where are Biogen offices?

    Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 41 other locations.

  • How many offices does Biogen have?

    Biogen has 46 offices.